SELECT id, `name`, primary_key, `key`, treemapgroup, name_cn, zacks_table_name, compare_key, compare_display_name from gurufocu_main.financial_definition where termpagedisplay=1 and `key` = 'ForwardDividendYield' CRSP (CRISPR Therapeutics AG) Forward Dividend Yield %
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (NAS:CRSP) » Definitions » Forward Dividend Yield %

CRISPR Therapeutics AG (CRISPR Therapeutics AG) Forward Dividend Yield %

: 0.00% (As of Today)
View and export this data going back to 2016. Start your Free Trial

As of today (2024-04-19), the Forward Annual Dividend Yield of CRISPR Therapeutics AG is 0.00%.

As of today (2024-04-19), the Trailing Annual Dividend Yield of CRISPR Therapeutics AG is 0.00%.

CRSP's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.59
* Ranked among companies with meaningful Forward Dividend Yield % only.

CRISPR Therapeutics AG's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison

For the Biotechnology subindustry, CRISPR Therapeutics AG's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CRISPR Therapeutics AG Forward Dividend Yield % Distribution

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's Forward Dividend Yield % falls into.


CRISPR Therapeutics AG Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

CRISPR Therapeutics AG  (NAS:CRSP) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

CRISPR Therapeutics AG Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

CRISPR Therapeutics AG (CRISPR Therapeutics AG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (NAS:CRSP) » Definitions » Forward Dividend Yield %
Comparable Companies
CYTK NUVL FOLD TRML KRYS BPMC AXSM CORT DNA INSM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
CRSP:Mexico
Address
Baarerstrasse 14, Zug, CHE, CH-6300
Website
https://www.crisprtx.com
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Executives
Samarth Kulkarni officer: Chief Business Officer C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Raju Prasad officer: Chief Financial Officer CRISPR THERAPEUTICS, INC., 105 W FIRST STREET, BOSTON MA 02127
Phuong Khanh Morrow officer: Chief Medical Officer C/O CRISPR THERAPEUTICS, 610 MAIN STREET, CAMBRIDGE MA 02139
Maria Fardis director C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Brendan Smith officer: Chief Financial Officer 29 HARTWELL AVENUE, LEXINGTON MA 02421
Michael John Tomsicek officer: Chief Financial Officer 28 OVERLOOK DRIVE, BEDFORD MA 01730
Bolzon Bradley J Phd director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Rodger Novak director, officer: Chief Executive Officer C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Harold Edward Fleming director C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Lawrence Otto Klein officer: Chief Business Officer C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET 7TH FLOOR, CAMBRIDGE MA 02139
James R. Kasinger officer: General Counsel and Secretary C/O CRISPR THERAPEUTICS, INC., 610 MAIN STREET, CAMBRIDGE MA 02139
Tony W Ho officer: See Remarks CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Douglas A Treco director 87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Pablo J Cagnoni director ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Katherine A High director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104